The National Institutes of Health (NIH) has chosen Advarra as its exclusive single institutional review board (sIRB) for clinical trials. This multi-year contract is valued at over $13 million.

Advarra’s expertise in project management and administrative oversight for sIRBs, coupled with its robust digital platform and extensive experience, were key factors in the decision.

Advarra’s leadership in research review solutions and clinical research technology has earned the trust of top global biopharma sponsors, CROs, and site investigators. Its solutions streamline trial operations, enhance patient safety, and accelerate clinical research while ensuring compliance.

The FDA’s anticipated mandate for sIRBs in multi-center clinical trials and the NIH’s existing sIRB policy have driven the adoption of sIRBs. Advarra’s selection as the NIH’s sIRB for NIAID is a testament to its capabilities.

Throughout its 35-year history, Advarra has consistently exceeded expectations in providing central IRB services. Its commitment to quality, scalability, and innovative technology has ensured the successful oversight of over 27,000 studies. Advarra played a vital role in Operation Warp Speed, providing IRB services for critical COVID research.

With this contract, the NIH acknowledges Advarra’s exceptional expertise and reinforces the importance of sIRBs in streamlining clinical trials and protecting human subjects. Advarra’s experience and innovative solutions will continue to support the NIH’s mission to advance medical research and improve public health.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.